A naukri.com initiative
Bioengineer
1w
284
Image Credit: Bioengineer
Breakthrough Local Therapy for Osteolytic Bone Disease in Multiple Myeloma Unveiled
- Researchers led by Professor Dirk Hose have developed a biomaterial (named 'sicXer') designed to mimic healthy bone to treat multiple myeloma.
- The biodegradable mesoporous silica-collagen xerogel bolsters the healing process and reduces the activity of osteoclasts, a type of cell that eats away at bone tissue.
- Simultaneously sicXer strengthens the bone tissue and opens up a framework for a localized drug delivery system.
- The researchers then developed 'boXer', a drug-loaded version of sicXer incorporating bortezomib, a drug used to treat multiple myeloma.
- The bortezomib in boXer suppresses the proliferation of myeloma cells, while simultaneously stimulating bone regeneration.
- Preclinical trials revealed that boXer could suppress myeloma cell proliferation in the bone tissue without toxic side effects.
- The next hurdle is clinical testing, after which sicXer and boXer could form part of a comprehensive treatment strategy for multiple myeloma patients.
- Researchers are currently on the verge of advancing towards clinical testing after promising preclinical trials.
- sicXer and boXer may become staples of comprehensive multiple myeloma treatment, transforming how the disease is approached.
- Researchers anticipate the biodegradable materials may also have implications for non-malignant bone degenerative diseases.
Read Full Article
17 Likes
For uninterrupted reading, download the app